Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer
AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer...
Cancer
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology...
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, Feb....
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento...
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to...
Genetic Technologies Announces $5 Million Registered Direct Offering
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global...
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference Halle (Saale) / Munich, Germany, February 3,...
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
Dr. Pamela Bush Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer EAGAN, Minn., Feb. 03, 2023 (GLOBE...
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 -...
GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader...
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ETHAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE)...
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference
CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM(a)(b), revenues increased 14%Full...
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Expects to Commence Phase 2a of CAReS During the First Quarter of 2023SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE)...
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
International Myeloma Foundation (IMF) Returns to In-Person Patient and Family Seminars in 2023, Announces Boca Raton Event
BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first...
Lisata Therapeutics Announces Participation in Upcoming Conferences in February
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging...